Sentences with word «olaparib»

They noted that a phase I trial of olaparib in combination with an ATM inhibitor known as AZD0156 is currently ongoing in patients with solid tumors.

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

The new study is also the first to identify which genetic mutations prostate cancers use to resist treatment with olaparib.

Samples that were resistant and treated with the PARP inhibitor olaparib showed a higher percentage of RAD51 - positive cells than those that were PARP inhibition — sensitive (36 % vs 5 %; P =.0017).

Clinicians are currently worried that breast cancer patients with low or absent BRCA1 may become resistant to therapeutic agents such as Olaparib.

Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza).

«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Boston.

In this study, the researchers tested the effects of Olaparib on the tumors formed by human breast cancer cells injected into mice.

«The results from this innovative clinical trial are very promising and highlight the potential for olaparib — and other PARP inhibitors — to treat a wide range of cancers.

The results will lead on to the start of TOPARP - B, a second part of the trial in which only men with detectable DNA repair mutations will receive olaparib.

He is currently leading the TOPARP trial, which is finding out whether a drug called olaparib (Lynparza) improves survival for men with advanced prostate cancer that has stopped responding to treatment.

Any previous treatment with PARP inhibitor, including olaparib.

The researchers found that women who took olaparib had a median of 8.4 months before their cancer came back, compared to 4.8 months for those on the placebo.

* The majority of patients were then given olaparib in combination with the chemotherapy drug temozolomide.

The results are extremely encouraging, suggesting that men with prostate cancers that contain defective DNA repair genes may benefit from olaparib treatment.»

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.

At this stage, PARP inhibitors are being tested in prostate cancer treatment, with a phase II clinical trial of Olaparib demonstrating increased radiologic progression - free survival in patients with metastatic prostate cancer displaying genomic aberrations indicative of HR repair defects.

Olaparib blocks this second repair pathway by inhibiting an enzyme called poly ADP ribose polymerase (PARP).

Olaparib stopped prostate cancer growth, generating falls in prostate specific antigen (PSA) levels, falls in circulating tumour cell counts in the blood, and radiological responses on CT scans and MRI.

Professor Steve Jackson, Head of Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute — whose CRUK - funded research led him to establish and scientifically lead the company KuDOS, which developed olaparib — said:

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not received Prior VEGF Therapy

Olaparib targets a molecule called PARP, and exploits weaknesses in cancer cells» ability to repair damage to their DNA.

Despite toxicity, olaparib maintenance therapy is associated with improved patient - reported symptoms outcomes and improved quality - adjusted progression - free survival among patients with germline BRCA mutation - positive, platinum - sensitive relapsed serious ovarian cancer.

An international research team, led by University College London's Professor Jonathan Ledermann, carried out a trial to see whether olaparib could have a role to play in preventing ovarian cancer from coming back in this group of patients.

Overall survival data are not yet available, as half of olaparib users had not relapsed at the time of data analysis.

Cancer Research UK, who did not fund the trial but have played an important role in the development of PARP inhibitors like olaparib, said the results highlighted their potential.

Researchers evaluated the maximum tolerated schedule and also measured olaparib exposure in tumour core, tumour margin and plasma following four doses.

The researchers also identified a way to safely combine both drugs by giving olaparib intermittently, minimising dangerous side effects.

** Olaparib was detected in 73 of 74 tumour core specimens from 27 patients (mean concentration: 588nM).

The OPARATIC trial has paved the way for two additional clinical trials — PARADIGM and PARADIGM - 2 — testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.

Larger clinical trials are now needed but, if the results of this phase - II trial are confirmed in future, maintenance therapy with olaparib could form a new treatment approach to prevent recurrences or prolong remission in women who have recently undergone chemotherapy for ovarian cancer.

«This suggests that PGAM1 inhibitors can sensitize cancers to PARP inhibitors such as Olaparib, thereby expanding the benefits of PARP inhibitors to BRCA1 / 2 - proficient cancers, particularly triple - negative breast cancers that currently lack effective therapies,» says author Min Huang.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

«Murine study finds potential boost for ovarian cancer drug Olaparib.»

As of March 2014, median progression - free survival was 9.2 months for olaparib and 16.7 months for the combination therapy, which is a significant advantage.

27 patients underwent surgery and 35 received olaparib / TMZ.

Tumours shrank in about 60 % of women who received the targeted drug, called olaparib (Lynparza), compared with 29 % of those who received chemotherapy.

Within eight weeks of finishing their chemotherapy, trial participants started to take olaparib or a placebo (dummy pill).

«We are really excited to now be moving forward with the next phase of our trial, which will be a key step in the evaluation of olaparib in advanced prostate cancer.»

They found that cancer cells had acquired new genetic changes that cancelled out the original errors in DNA repair — particularly in the genes BRCA2 and PALB2 — that had made the cancer susceptible to olaparib in the first place.

Researchers at the ICR and The Royal Marsden collected blood samples from 49 men at The Royal Marsden with advanced prostate cancer enrolled in the TOPARP - A phase II clinical trial of olaparib.

Olaparib is good at killing cancer cells that have errors in genes that have a role in repairing damaged DNA such as BRCA1 or BRCA2.

The researchers also performed a detailed examination of the genetic changes that occurred in cancer DNA from patients who had stopped responding to olaparib.

Olaparib had no effect on tumors formed by breast cancer cells containing functional BRCA1 and BRCA2 genes.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.